GLS and neoplasm: In line with these clinical observations, the effector function of anti-tumour T cells is markedly improved if tumour cells lose GLS activity in vitro using cutting-edge techniques such as CRISPR-Cas9, attributable to a reduction in tumour-cell-driven glutamine depletion and a concomitant increase in local glutamine availability to T cells [8].